Deals of the Week: AstraZeneca’s Neuroscience Deals, Verastem/Pfizer, Alnylam/Ascletis
Executive Summary
AstraZeneca’s neuroscience innovative medicines unit (iMED) begins to take shape through a pair of deals with Link Medicine Corp. and with four academic labs.